Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Recursion Pharmaceuticals...

    NASDAQ: RXRX · Real-Time Price · USD
    5.01
    -0.39 (-7.22%)
    At close: Jun 27, 2025, 3:59 PM
    5.04
    0.50%
    After-hours: Jun 27, 2025, 05:58 PM EDT

    Recursion Pharmaceuticals Statistics

    Share Statistics

    Recursion Pharmaceuticals has 399.66M shares outstanding. The number of shares has increased by 71.69% in one year.

    Shares Outstanding

    n/a
    		 399.66M

    Shares Change (YoY)

    n/a
    		 71.69%

    Shares Change (QoQ)

    n/a
    		 2.96%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 310.78M

    Failed to Deliver (FTD) Shares

    n/a
    		 319,549

    FTD / Avg. Volume

    n/a
    		 1.3%

    Short Selling Information

    The latest short interest is 120.08M, so 29.54% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 120.08M

    Short % of Shares Out

    n/a
    		 29.54%

    Short % of Float

    n/a
    		 31.87%

    Short Ratio (days to cover)

    n/a
    		 3.27

    Valuation Ratios

    The PE ratio is -4 and the forward PE ratio is -4.72. Recursion Pharmaceuticals's PEG ratio is -0.57.

    PE Ratio

    n/a
    		 -4

    Forward PE

    n/a
    		 -4.72

    PS Ratio

    n/a
    		 31.5

    Forward PS

    n/a
    		 10.3

    PB Ratio

    n/a
    		 1.79

    P/FCF Ratio

    n/a
    		 -4.97

    PEG Ratio

    n/a
    		 -0.57
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Recursion Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.1.

    Current Ratio

    n/a
    		 3.81

    Quick Ratio

    n/a
    		 3.81

    Debt / Equity

    n/a
    		 0.1

    Debt / EBITDA

    n/a
    		 -0.25

    Debt / FCF

    n/a
    		 -0.29

    Interest Coverage

    n/a
    		 -304.71

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $73,548.75

    Profits Per Employee

    n/a
    		 $-579,576.25

    Employee Count

    n/a
    		 800

    Asset Turnover

    n/a
    		 0.04

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1.13M

    Effective Tax Rate

    n/a
    		 0.24%

    Stock Price Statistics

    The stock price has increased by -33.2% in the last 52 weeks. The beta is 0.83, so Recursion Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.83

    52-Week Price Change

    n/a
    		 -33.2%

    50-Day Moving Average

    n/a
    		 4.92

    200-Day Moving Average

    n/a
    		 6.34

    Relative Strength Index (RSI)

    n/a
    		 50.95

    Average Volume (20 Days)

    n/a
    		 24,571,814

    Income Statement

    In the last 12 months, Recursion Pharmaceuticals had revenue of 58.84M and earned -463.66M in profits. Earnings per share was -1.69.

    Revenue

    n/a
    		 58.84M

    Gross Profit

    n/a
    		 13.6M

    Operating Income

    n/a
    		 -479M

    Net Income

    n/a
    		 -463.66M

    EBITDA

    n/a
    		 -426.72M

    EBIT

    n/a
    		 -463.22M

    Earnings Per Share (EPS)

    n/a
    		 -1.69
    Full Income Statement

    Balance Sheet

    The company has 594.35M in cash and 108.49M in debt, giving a net cash position of 485.86M.

    Cash & Cash Equivalents

    n/a
    		 594.35M

    Total Debt

    n/a
    		 108.49M

    Net Cash

    n/a
    		 485.86M

    Retained Earnings

    n/a
    		 -1.43B

    Total Assets

    n/a
    		 1.31B

    Working Capital

    n/a
    		 442.16M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -359.17M and capital expenditures -13.7M, giving a free cash flow of -372.87M.

    Operating Cash Flow

    n/a
    		 -359.17M

    Capital Expenditures

    n/a
    		 -13.7M

    Free Cash Flow

    n/a
    		 -372.87M

    FCF Per Share

    n/a
    		 -1.36
    Full Cash Flow Statement

    Margins

    Gross margin is 23.12%, with operating and profit margins of -814.09% and -788.02%.

    Gross Margin

    n/a
    		 23.12%

    Operating Margin

    n/a
    		 -814.09%

    Pretax Margin

    n/a
    		 -789.93%

    Profit Margin

    n/a
    		 -788.02%

    EBITDA Margin

    n/a
    		 -725.24%

    EBIT Margin

    n/a
    		 -814.09%

    FCF Margin

    n/a
    		 -633.71%

    Dividends & Yields

    RXRX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RXRX is $6, which is 19.8% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 19.8%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 0.15

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist